NASDAQ:DRTX (DRTX) (DRTX) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free DRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (DRTX) alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About (DRTX) Stock (NASDAQ:DRTX)Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.Read More Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. DRTX Stock News HeadlinesApril 17, 2024 | morningstar.comSynlait Milk Ltd SMLMarch 29, 2024 | nasdaq.comFSLR Crosses Above Key Moving Average LevelMay 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. November 16, 2023 | msn.comAttorney and parent speak on Disability Rights Texas' filed complaint on ECISDNovember 15, 2023 | msn.comECISD responds to Disability Rights complaintOctober 12, 2023 | msn.comHISD teachers accuse district of prohibiting disability accommodations for studentsJuly 14, 2023 | msn.comStorm Clouds: Shanahan Almost Hired by Rams?July 5, 2023 | msn.comWhen Raj Kapoor revealed why he never married Nargis, said that he ‘drew a line’ from day one and wife Krishna Raj ‘undersood’: ‘Nobody cheated anybody’May 4, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. July 5, 2023 | msn.comUAE: Discounts announced for zip line, Jebel Jais sledder experiences; adventure park to remain open throughout summerApril 8, 2023 | msn.comUFC 287 Loses Bout In Final HourMarch 15, 2023 | msn.comEddie Nketiah and Folarin Balogun both face summer Arsenal exit question after £27m transferFebruary 25, 2023 | msn.comDisability rights group calls on state to address Austin ISD's ongoing delayed evaluationsFebruary 7, 2023 | msn.comSt. Andrews to leave the 700-year-old Swilcan Bridge aloneJanuary 23, 2023 | msn.comCampus notesJanuary 12, 2023 | msn.comUK Prime Minister Comes Under Fire For 30 Minute Private Jet Flight To LeedsJanuary 11, 2023 | msn.comMore than half of people in Cambridge have higher education qualificationNovember 2, 2022 | msn.comAlec Bohm has progressed from hater to hitter, turning early-season boos to cheersOctober 21, 2022 | msn.comTrump ally Steve Bannon faces sentencing for contemptAugust 14, 2022 | msn.comAamir Khan joins PM Modi’s ‘Har Ghar Tiranga’ campaign, displays flag at his houseAugust 2, 2022 | msn.comWatch: Messi stops security from dragging young fan away as he struggles to take selfie with PSG starMarch 2, 2022 | msn.comTarrant County voters share their experiences, issues faced during primary electionNovember 11, 2021 | msn.comJudge knocks down Abbott's ban on mask mandates in Texas schoolsSee More Headlines Receive DRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (DRTX) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:DRTX CUSIP26658A10 CIK1544116 WebN/A Phone+1-312-2197000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report DRTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of (DRTX) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (DRTX) investors own include Allena Pharmaceuticals (ALNA), Arbutus Biopharma (ABUS), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Five Prime Therapeutics (FPRX), Glu Mobile (GLUU) and Inovio Pharmaceuticals (INO). This page (NASDAQ:DRTX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (DRTX) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
